新技术的进步与生物信息学相结合，导致了其他基因的发现，例如与耐药性相关的长非编码 RNA (lncRNA)。 LncRNA由200多个核苷酸组成，不具有任何蛋白质编码功能。这些lncRNA在物种间表现出较低的保守性，通常表达水平较低，并且通常对特定组织和发育阶段表现出高度特异性。 LncRNA MALAT1 在基因组功能的各个方面发挥着至关重要的调节作用，包括基因转录、剪接和表观遗传学。此外，它还参与与细胞周期、细胞分化、发育和多能性相关的生物过程。最近，MALAT1作为一种导致耐药性或敏感性的新机制出现，引起了癌症研究领域的广泛关注。本综述旨在探讨 MALAT1 赋予癌细胞对化疗和放疗耐药性的机制。© 2024。作者获得 Springer Science Business Media, LLC（Springer Nature 旗下子公司）的独家许可。

The advancement of novel technologies, coupled with bioinformatics, has led to the discovery of additional genes, such as long noncoding RNAs (lncRNAs), that are associated with drug resistance. LncRNAs are composed of over 200 nucleotides and do not possess any protein coding function. These lncRNAs exhibit lower conservation across species, are typically expressed at low levels, and often display high specificity towards specific tissues and developmental stages. The LncRNA MALAT1 plays crucial regulatory roles in various aspects of genome function, encompassing gene transcription, splicing, and epigenetics. Additionally, it is involved in biological processes related to the cell cycle, cell differentiation, development, and pluripotency. Recently, MALAT1 has emerged as a novel mechanism contributing to drug resistance or sensitivity, attracting significant attention in the field of cancer research. This review aims to explore the mechanisms through which MALAT1 confers resistance to chemotherapy and radiotherapy in cancer cells.© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.